首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 11期原发性胆汁性胆管炎 => 专家论坛 =>对熊去氧胆酸应答不佳的原发性..
对熊去氧胆酸应答不佳的原发性胆汁性胆管炎治疗策略
Therapeutic strategies for patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid
文章发布日期:2017年10月11日  来源:  作者:施漪雯,尤红  点击次数:290次  下载次数:78次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:原发性胆汁性胆管炎(PBC)的治疗近年来主要应用熊去氧胆酸,而增长的患者人数、应答不佳和治疗不耐受的出现对治疗方案提出了挑战,新药奥贝胆酸的获批为PBC患者带来了希望,联合使用贝特类药物也具有前景,更多的试验正在进行之中。新型药物如单克隆抗体、成纤维细胞生长因子19、钠依赖性胆汁酸转运蛋白抑制剂等虽然疗效数据有限,但为PBC治疗提供了新的方向。通过个性化随访以及分层治疗,PBC患者的管理将进入新的阶段。
【Abstract】:In recent years, ursodeoxycholic acid is commonly used for the treatment of primary biliary cholangitis (PBC); however, the growing number of PBC patients and the occurrence of suboptimal response and treatment intolerance pose a great challenge to treatment regimens. The approval of the new drug obeticholic acid brings hope to PBC patients, and a combination of fibrates also has a promising future. More studies are in progress. Although new drugs, such as monoclonal antibody, fibroblast growth factor 19, and sodium-dependent bile acid transporter inhibitor, have limited efficacy data, they provide new directions for the treatment of PBC. With the help of individualized follow-up and stratified therapy, the management of PBC patients will enter a new stage.
【关键字】:胆管炎, 胆汁性; 熊脱氧胆酸; 鹅脱氧胆酸; 氯贝酸; 糖皮质激素类; 抗体, 单克隆
【Key words】:cholangitis, biliary; ursodeoxycholic acid; chenodeoxycholic acid; clofibric acid; glucocrticoids; antibodies, monoclonal
【引证本文】:施漪雯, 尤红. 对熊去氧胆酸应答不佳的原发性胆汁性胆管炎治疗策略[J]. 临床肝胆病杂志, 2017, 33(11): 2101-2104.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号